Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Variant||ETV6 - NTRK2|
|Protein Effect||gain of function - predicted|
|Gene Variant Descriptions||ETV6-NTRK2 results in the fusion of ETV6 and NTRK2 (PMID: 26939704) resulting in cytokine-independent cell growth in culture, increased downstream signaling in vitro, and promotes tumor formation in mice (PMID: 29920189). ETV6-NTRK2 has been identified in acute myeloid leukemia (PMID: 29920189).|
|Associated Drug Resistance|
|Molecular Profile||Protein Effect||Treatment Approaches|
|ETV6 - NTRK2||gain of function - predicted||Trk Receptor Inhibitor (Pan) Larotrectinib|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ETV6 - NTRK2||Advanced Solid Tumor||sensitive||DS6051b||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to treatment with DS6051b in culture, demonstrating cell growth inhibition (PMID: 31399568).||31399568|
|ETV6 - NTRK2||Advanced Solid Tumor||sensitive||Repotrectinib||Preclinical - Cell culture||Actionable||In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing ETV6-NTRK2 in culture (PMID: 30093503).||30093503|
|ETV6 - NTRK2||Advanced Solid Tumor||sensitive||Entrectinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591).||26884591|
|ETV6 - NTRK2||Advanced Solid Tumor||sensitive||Entrectinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Rozlytrek (entrectinib), resulting in inhibition of cell proliferation in culture (PMID: 26939704).||26939704|
|ETV6 - NTRK2||acute myeloid leukemia||sensitive||Larotrectinib||Case Reports/Case Series||Actionable||In a clinical study, a patient with secondary AML achieved a partial remission when treated with Vitrakvi (larotrectinib), showing complete elimination of the cell population harboring ETV6-NTRK2, and the patient-derived xenograft (PDX) model harboring ETV6-NTRK2 showed sensitivity to treatment with Vitrakvi (larotrectinib), demonstrating a decrease in ETV6-NTRK2-expressing cells (PMID: 29920189).||29920189|